DNMT1 and neoplasm: Other authors reported that the deletion of DNMT1 in mice decreased the number of Treg cells in lymphoid organs [65] and that patients on trial with guadecitabine and anti-PD1 (pembrolizumab) showed a reduced number of Treg cells compared to baseline in tumor biopsies [66].